Figures & data
Figure 2. The risk management process for addressing use-related risks with the redesigned follitropin alfa pen.
![Figure 2. The risk management process for addressing use-related risks with the redesigned follitropin alfa pen.](/cms/asset/b95f2018-e46c-4b38-b1fb-17035671fb51/iedd_a_1033395_f0002_ob.jpg)
Figure 3. Modification of the redesigned pen device. Change from conical (A) to cylindrical (B) needle cap to mitigate use error observed in the pre-validation studies.
![Figure 3. Modification of the redesigned pen device. Change from conical (A) to cylindrical (B) needle cap to mitigate use error observed in the pre-validation studies.](/cms/asset/a971bafb-7efa-453f-9cec-5ee87294b067/iedd_a_1033395_f0003_oc.jpg)
Table 1. Demographic characteristics and prior injection experience of participants in the validation studies.
Table 2. Critical use errors in A) validation study and B) mitigation validation study.